MedinCell S.A. is a pharmaceutical company that develops a portfbuy
stock in good hands
sl 4.5
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular
−1.02EUR
−32.01 MEUR
9.89 MEUR
20.69 M
About MEDINCELL S.A.
Sector
CEO
Christophe Douat
Headquarters
Jacou
Website
Employees (FY)
143
Founded
2002
ISIN
FR0004065605
FIGI
BBG00M0C8GJ0
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. It focuses on combining its proprietary BEPO technology with active ingredients already known and marketed; it controls the regular delivery of a drug at the optimal therapeutic dose. The company was founded by Anh Nguyen and Christophe Douat on January 9, 2003 and is headquartered in Jacou, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MEDCL is 11.10 EUR — it has increased by 1.83% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange MEDINCELL S.A. stocks are traded under the ticker MEDCL.
MEDINCELL S.A. is going to release the next earnings report on Jun 25, 2024. Keep track of upcoming events with our Earnings Calendar.
MEDCL stock is 3.90% volatile and has beta coefficient of 0.58. Check out the list of the most volatile stocks — is MEDINCELL S.A. there?
One year price forecast for MEDINCELL S.A. has a max estimate of 22.00 EUR and a min estimate of 12.00 EUR.
Yes, you can track MEDINCELL S.A. financials in yearly and quarterly reports right on TradingView.
MEDCL stock has risen by 20.00% compared to the previous week, the month change is a 16.47% rise, over the last year MEDINCELL S.A. has showed a 23.20% increase.
MEDCL net income for the last quarter is −8.16 M EUR, while the quarter before that showed −18.26 M EUR of net income which accounts for 55.33% change. Track more MEDINCELL S.A. financial stats to get the full picture.
Today MEDINCELL S.A. has the market capitalization of 316.54 M, it has decreased by 4.10% over the last week.
No, MEDCL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MEDCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDINCELL S.A. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 143.00 employees. See our rating of the largest employees — is MEDINCELL S.A. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDINCELL S.A. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDINCELL S.A. stock shows the strong buy signal. See more of MEDINCELL S.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MEDINCELL S.A. future price: according to them, MEDCL price has a max estimate of 22.00 EUR and a min estimate of 12.00 EUR. Read a more detailed MEDINCELL S.A. forecast: see what analysts think of MEDINCELL S.A. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDINCELL S.A. EBITDA is −22.95 M EUR, and current EBITDA margin is −264.66%. See more stats in MEDINCELL S.A. financial statements.